Intel joins Europe’s MHealth Alliance

  • 26 November 2010

The European MHealth Alliance (EuMHA ) has welcomed Intel as a Foundation Member.

Intel have agreed to chair the innovation workstream and will join the international leadership panel, which advises the Board of EuMHA on strategy.

David McCarron, EMEA healthcare manager of Intel said "We are delighted to be part of EuMHA which is providing leadership in Europe in what is a fast growing but new and fragmented sector. Today, the healthcare industry worldwide is far from healthy. Mobile health solutions should help to give better access to care at acceptable costs and improve quality and security.”

McCarron added: “We believe the opportunity to work with the membership mix of EuMHA which includes Healthcare Providers, Research Institutes and companies, large and small will deliver much needed focus.”

Ilkka Vartiainen, chief executive of EuMHA, welcomed Intel’s decision to join EuMHA and chair the innovation panel and take their seat on the international leadership panel.

Intel has worked with clinicians and healthcare organisations worldwide and conducted extensive research to design platforms that meet the needs of mobile healthcare professionals in hospital, clinic and community settings in a variety of environments.

Subscribe To Our Newsletters

Subscribe to our newsletter

Subscribe To Our Newsletter

Related News

Midlands trust launches digital medicines management system

Midlands trust launches digital medicines management system

University Hospitals Coventry and Warwickshire (UHCW) NHS Trust has gone live with an interoperable digital medicines management system.
Digital Health Coffee Time Briefing ☕

Digital Health Coffee Time Briefing ☕

Today's briefing features quantum simulation for drug discovery tech and new digital healthcare infrastructure in Morocco.
Patients at risk as NHS and online prescriptions not joined up

Patients at risk as NHS and online prescriptions not joined up

HSSIB has warned that gaps in information sharing between the NHS and independent prescribing services could put patients at risk.